Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
August 15, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
August 10, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ISELIN, N.J., Aug. 10, 2022 (GLOBE...
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
August 04, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 05, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
June 14, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA) ISELIN, N.J., June 14,...
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
May 31, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
May 13, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be announced in June 2022Advancing ONS-5010...
Outlook Therapeutics to Participate in Retina World Congress 2022
May 10, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
May 09, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...